Amyloid beta25-35 impairs docosahexaenoic acid efflux by down-regulating fatty acid transport protein 1 (FATP1/SLC27A1) protein expression in human brain capillary endothelial cells

16Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Decreased levels of docosahexaenoic acid (DHA), an endogenous neuroprotective compound, in the brain are associated with the development of Alzheimer’s disease (AD). We previously showed that DHA is a substrate of fatty acid transport protein 1 (FATP1/SLC27A1), and FATP1 is localized at the abluminal membrane of brain capillary endothelial cells. We hypothesized that amyloid β (Aβ) decreases FATP1-mediated cellular efflux (i.e. supply to the brain) of DHA at the blood–brain barrier (BBB). Here, we tested this hypothesis using a human cerebral microvascular endothelial cell line, human cerebral microvessel endothelial cells (hCMEC/D3), as a BBB model. The efflux of DHA-d5 by hCMEC/D3 cells increased time-dependently up to 3 min. Knock-down of FATP1 with specific siRNA indicated that FATP1-mediated efflux accounts for 47.0% of this DHA-d5 efflux. In hCMEC/D3 cells treated with Aβ25–35 (10 μM/24 h), which we employed as an in vitro model of the BBB in AD, FATP1 protein expression in the plasma membrane was decreased by 96.0%, which was greater than the decrease in the whole-cell lysate, and the DHA-d5 efflux was decreased by 68.3%. Of this 68.3% decrease, 45.1% (47.0 × 0.96) is accounted for by the decrease in FATP1-mediated efflux and the remaining 23.2% is presumably mediated by other mechanism(s). Thus, we have established for the first time that FATP1 is a major contributor to DHA efflux from human brain capillary endothelial cells, and its efflux activity at the abluminal membrane of the cells is blocked by Aβ. This may explain the decreased DHA level in the brain of AD patients. Open Science Badges: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/. (Figure presented.).

References Powered by Scopus

The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics

12013Citations
N/AReaders
Get full text

Alzheimer's disease: Genes, proteins, and therapy

5475Citations
N/AReaders
Get full text

Blood-brain barrier-specific properties of a human adult brain endothelial cell line

1137Citations
N/AReaders
Get full text

Cited by Powered by Scopus

β-Glucan-Induced Trained Immunity Protects against Leishmania braziliensis Infection: a Crucial Role for IL-32

121Citations
N/AReaders
Get full text

Dysfunction of the blood–brain barrier in Alzheimer's disease: Evidence from human studies

92Citations
N/AReaders
Get full text

Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?

44Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ochiai, Y., Uchida, Y., Tachikawa, M., Couraud, P. O., & Terasaki, T. (2019). Amyloid beta25-35 impairs docosahexaenoic acid efflux by down-regulating fatty acid transport protein 1 (FATP1/SLC27A1) protein expression in human brain capillary endothelial cells. Journal of Neurochemistry, 150(4), 385–401. https://doi.org/10.1111/jnc.14722

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

59%

Researcher 4

24%

Professor / Associate Prof. 3

18%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 7

44%

Neuroscience 5

31%

Pharmacology, Toxicology and Pharmaceut... 2

13%

Agricultural and Biological Sciences 2

13%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free